Drug intelligence / Profile preview

n-[1,3-di(4-morpholinyl)-2-propanyl]-3-(α-d-galactopyranosyloxy)-5-nitrobenzamide

Development stage: Unknown
Modality: Small Molecules

Overview

N-[1,3-Di(4-morpholinyl)-2-propanyl]-3-(α-D-galactopyranosyloxy)-5-nitrobenzamide is a synthetic small molecule that features an α-D-galactopyranose moiety linked to a 5-nitrobenzamide core via an ether linkage. The compound also contains two morpholine rings attached to a propyl linker. There is no widely published information on its mechanism of action or clinical development status in major drug databases or literature as of current knowledge. It appears to be referenced in the context of drug target research but not as a marketed or investigational drug[7].

Other names: N-[1,3-Di(4-morpholinyl)-2-propanyl]-3-(α-D-galactopyranosyloxy)-5-nitrobenzamide

Beyond the preview

Go deeper on n-[1,3-di(4-morpholinyl)-2-propanyl]-3-(α-d-galactopyranosyloxy)-5-nitrobenzamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on n-[1,3-di(4-morpholinyl)-2-propanyl]-3-(α-d-galactopyranosyloxy)-5-nitrobenzamide.

Explore the full profile